On the performances of Intensity Modulated Protons, RapidArc and Helical Tomotherapy for selected paediatric cases

Fogliata, Antonella; Yartsev, Slav; Nicolini, Giorgia; Clivio, Alessandro; Vanetti, Eugenio; Wyttenbach, Rolf; Bauman, Glenn; Cozzi, Luca
January 2009
Radiation Oncology;2009, Vol. 4, p1
Academic Journal
Background: To evaluate the performance of three different advanced treatment techniques on a group of complex paediatric cancer cases. Methods: CT images and volumes of interest of five patients were used to design plans for Helical Tomotherapy (HT), RapidArc (RA) and Intensity Modulated Proton therapy (IMP). The tumour types were: extraosseous, intrathoracic Ewing Sarcoma; mediastinal Rhabdomyosarcoma; metastastis of base of skull with bone, para-nasal and left eye infiltration from Nephroblastoma of right kidney; metastatic Rhabdomyosarcoma of the anus; Wilm's tumour of the left kidney with multiple liver metastases. Cases were selected for their complexity regardless the treatment intent and stage. Prescribed doses ranged from 18 to 53.2 Gy, with four cases planned using a Simultaneous Integrated Boost strategy. Results were analysed in terms of dose distributions and dose volume histograms. Results: For all patients, IMP plans lead to superior sparing of organs at risk and normal healthy tissue, where in particular the integral dose is halved with respect to photon techniques. In terms of conformity and of spillage of high doses outside targets (external index (EI)), all three techniques were comparable; CI90% ranged from 1.0 to 2.3 and EI from 0 to 5%. Concerning target homogeneity, IMP showed a variance (D5%-D95%) measured on the inner target volume (highest dose prescription) ranging from 5.9 to 13.3%, RA from 5.3 to 11.8%, and HT from 4.0 to 12.2%. The range of minimum significant dose to the same target was: (72.2%, 89.9%) for IMP, (86.7%, 94.1%) for RA, and (79.4%, 94.8%) for HT. Similarly, for maximum significant doses: (103.8%, 109.4%) for IMP, (103.2%, 107.4%) for RA, and (102.4%, 117.2%) for HT. Treatment times (beamon time) ranged from 123 to 129 s for RA and from 146 to 387 s for HT. Conclusion: Five complex pediatric cases were selected as representative examples to compare three advanced radiation delivery techniques. While differences were noted in the metrics examined, all three techniques provided satisfactory conformal avoidance and conformation.


Related Articles

  • MediGene begins trials of cancer killing virus.  // PharmaWatch: Cancer;October 2004, Vol. 3 Issue 10, p12 

    This article reports that the German-American biotech company, MediGene AG, has initiated a clinical trial of NV1020, a potential treatment for liver metastases developing from colorectal cancer. The patients participating in the trial suffer from colorectal adenocarcinoma, which cannot be...

  • Progression-free survival increased after perioperative chemotherapy and surgery. Lenz, Heinz-Josef // Hem/Onc Today;5/10/2008, Vol. 9 Issue 8, p37 

    The article focuses on a parallel-group study conducted by researchers from several institutes in Europe. It was participated by 364 patients with up to four liver metastases who were assigned to either six cycles of FOLFOX4 regimen, which includes oxaliplatin, 5-Fluorouracil and leucovovin,...

  • Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. Vogl, Thomas; Schwarz, Wolfram; Eichler, Katrin; Hochmuth, Kathrin; Hammerstingl, Renate; Jacob, Ursula; Scheller, Albert; Zangos, Stephan; Heller, Matthias // Journal of Cancer Research & Clinical Oncology;Nov2006, Vol. 132 Issue 11, p745 

    To define the maximum tolerated dose (MTD) of hepatic intraarterial chemotherapy with gemcitabine, administered with and without starch microspheres, in patients with inoperable intrahepatic cholangiocarcinomas and liver metastases of pancreatic carcinomas. Gemcitabine was administered on days 1...

  • Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. Nasti, G.; Ottaiano, A.; Berretta, M.; Delrio, P.; Izzo, F.; Cassata, A.; Romano, C.; Facchini, G.; Scala, D.; Mastro, A.; Romano, G.; Perri, F.; Iaffaioli, R. V. // Cancer Chemotherapy & Pharmacology;Jul2010, Vol. 66 Issue 2, p209 

    The standard treatment of CRC patients with hepatic metastases is systemic chemotherapy; however, 5-year survival is disappointingly poor despite recent advances. On the other hand, in patients who undergo immediate radical surgical resection of hepatic metastases, 5-year survival reaches...

  • Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. T Ohki // Gut;Jun2009, Vol. 58 Issue 6, p839 

    BACKGROUND AND AIM: Visceral fat accumulation reportedly increases the risk of hepatocellular carcinoma (HCC) development in patients with chronic liver disease. However, it has not beeen fully elucidated whether visceral fat accumulation increases the risk of HCC recurrence after curative...

  • Risk Factors for Postoperative Delirium after Liver Resection for Hepatocellular Carcinoma. Yoshimura, Yasuko; Kubo, Shoji; Shirata, Kumiko; Hirohashi, Kazuhiro; Tanaka, Hiromu; Shuto, Taichi; Takemura, Shigekazu; Kinoshita, Hiroaki // World Journal of Surgery;Oct2004, Vol. 28 Issue 10, p982 

    We investigated risk factors for delirium in 100 patients who underwent liver resection for hepatocellular carcinoma. Postoperative delirium developed in 17 (17%). Univariate analysis revealed that advanced age (especially = 70 years old), a history of smoking, a decreased serum albumin...

  • Multi-institutional study of risk factors of liver metastasis from colorectal cancer: correlation with CD10 expression. Fujita, Shin; Taniguchi, Hirokazu; Yao, Takashi; Shimoda, Tadakazu; Ueno, Hideki; Hirai, Takashi; Ohue, Masayuki // International Journal of Colorectal Disease;Jun2010, Vol. 25 Issue 6, p681 

    The risk factors for liver metastasis from colorectal cancer are still unclear. We therefore evaluated the relationships between various clinicopathological factors, including CD10 expression, liver metastasis, and survival, in patients with colorectal cancer. Clinicopathological data for 1,025...

  • Colorectal Liver Metastases: an Update on Palliative Treatment Options. Konopke, Ralf; Roth, Johanna; Volk, Andreas; Pistorius, Steffen; Folprecht, Gunnar; Zoephel, Klaus; Schuetze, Christina; Laniado, Michael; Saeger, Hans-Detlev; Kersting, Stephan // Journal of Gastrointestinal & Liver Diseases;Mar2012, Vol. 21 Issue 1, p83 

    Only approximately 30% of patients with colorectal cancer liver metastasis qualify for curative therapy, which is in most cases liver lesion resection. Due primarily to the extent of the tumors and patient comorbidities, palliative therapy remains the only option in non-resection cases....

  • Radiofrequency Ablation of Hepatic Metastases from Thyroid Carcinoma. Marieke W.J.L.A.E. Wertenbroek; Thera P. Links; Ted R. Prins; John T.M. Plukker; Erik J. van der Jagt; Koert P. de Jong // Thyroid;Oct2008, Vol. 18 Issue 10, p1105 

    Background:Radiofrequency ablation (RFA) is performed for various types of liver tumors. It might also have a role in the palliative treatment of liver metastases from thyroid carcinoma.Summary:Three patients with liver metastases of thyroid carcinoma were retrieved from our database of 125...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics